Various biomarkers such as PD-L1 expression, tumour mutation burden (TMB), microsatellite instability, microbiome, hypoxia, interferon-gamma (IFN-γ), and extracellular matrix have been reported on order to increase response to immunotherapy in patients, receiving ICIs. Here, CD274 is linked to neoplasm.